@FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

 Washington, DC
FierceBiotech.com
Joined December 2008
  • Tweets29.7K
  • Following616
  • Followers103K
170Media
Celldex monoclonal antibody rebounds with a pair of phase 3 wins for chronic skin condition fiercebiotech.com/biotech/ce…

Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition

Celldex touted a

fiercebiotech.com
1
1
10
3,582
Novartis secures new radioligand in $900M deal fiercebiotech.com/biotech/no…

Novartis secures new radioligand in $900M deal as competition strengthens

As an imposing new competitor begins to take shape, radiopharma leader Novartis has

fiercebiotech.com
1
4
27
4,760
Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets. fiercebiotech.com/biotech/bo…

Boehringer, Envisagenics sign $1B multi-target oncology collaboration

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.  | Boehringer...

fiercebiotech.com
4
18
3,632
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes fiercebiotech.com/biotech/ro…

Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes

A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has 

fiercebiotech.com
2
15
3,595
A phase 3 study of Otsuka and Ionis’ ALS prospect hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals. fiercebiotech.com/biotech/ot…

Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug candidate has 

fiercebiotech.com
1
4
1
17
4,268
Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network. fiercebiotech.com/biotech/an…

Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Telix has struck a deal to buy ITM Isotope Technologies Munich | Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to...

fiercebiotech.com
1
1
1
9
3,590
Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of sleep disorders and into broader patient populations. fiercebiotech.com/biotech/pi…

With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’

Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of |...

fiercebiotech.com
3
2
14
3,737
China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status in innovative R&D. fiercebiotech.com/biotech/ch…

China targets 25% share of global first-in-class drugs in new 5-year plan

China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed for innovative R&D. | China is aiming to account for at least...

fiercebiotech.com
1
4
8
3,419
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope fiercebiotech.com/biotech/re…

Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope

New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope. | New-look Novo is digging deeper into its metabolic roots with...

fiercebiotech.com
1
7
4,114
Xenon pauses phase 3 depression trials after psychosis events fiercebiotech.com/biotech/xe…

Xenon pauses phase 3 depression trials after psychosis events

Xenon Pharmaceuticals has paused enro | The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.

fiercebiotech.com
1
10
3,835
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data fiercebiotech.com/biotech/br…

BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data

Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data. | Bristol Myers Squibb...

fiercebiotech.com
1
4
20
5,800
After a run of dealmaking, Gilead CEO Daniel O'Day told Fierce that any future M&A activity will only be done to complement the existing strategy. fiercebiotech.com/biotech/it… @GileadSciences

CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead Sciences’ CEO has told Fierce how the company’s efforts to expand into oncology and infl |...

fiercebiotech.com
1
20
4,531
A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate. fiercebiotech.com/biotech/jj…

J&J’s Contineum-partnered depression drug flunks another phase 2 test

A phase 2 trial of Johnson & Johnson’s JNJ-5120 has 

fiercebiotech.com
2
10
3,941
Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations. fiercebiotech.com/biotech/li…

Lilly cans early experimental obesity drug after ‘high bar’ not met

Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations. | Eli Lilly has put the kibosh on an early-stage obesity drug after...

fiercebiotech.com
4
1
15
6,281
Novo’s rebrand got off to a shaky start with news the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug. fiercebiotech.com/biotech/no…

Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis

Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two |...

fiercebiotech.com
4
5
4,021
Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal fiercebiotech.com/biotech/bi…

Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal

The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent | The FDA has put enrollment in trials of Biohaven’s epilepsy drug...

fiercebiotech.com
2
10
4,082
Massachusetts governor makes pre-election pitch to biotechs amid warning early-stage start-ups are "dying" fiercebiotech.com/biotech/ma…

Mass. governor makes pre-election pitch to biotechs amid warning early-stage start-ups are 'dying'

It may have seemed like an ordinary Wednesday afternoon at MassBio’s headquarters in Technology Square, but the black SUV parked outside was a telltale sign that the Cambridge, Massachusetts-based |...

fiercebiotech.com
1
5
3,902
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment. fiercebiotech.com/biotech/ku…

Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment. | Kura Oncology has spun out a biotech armed with $50 million in...

fiercebiotech.com
1
1
5
3,874
Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail fiercebiotech.com/biotech/ev…

Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail

Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has

fiercebiotech.com
1
4
3,720
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win fiercebiotech.com/biotech/ro…

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study. | Roivant’s $14 million bet on a pulmonary...

fiercebiotech.com
5
23
4,724
Load more